Histoplasmosis: A Common Infection Hiding in Plain Sight

Histoplasmosis is frequently introduced during medical training as a rare infectious disease, a diagnostic “zebra” that clinicians should remember but are unlikely to encounter often in practice. In reality, this framing contrasts with accumulating epidemiologic and clinical evidence. Histoplasma infections have been documented across nearly all regions of the United States and are increasingly recognized throughout the Americas, as well as parts of Africa and Asia.^1,2

The problem is not that histoplasmosis is uniformly common; rather, it is broadly distributed, often underdiagnosed, and capable of causing severe disease in populations least able to tolerate diagnostic delay. Part of this disconnect may stem from how these infections have historically been framed. Histoplasmosis is commonly grouped among the endemic mycoses, a term that is clinically familiar but may unintentionally reinforce diagnostic anchoring by implying strict geographic boundaries. A more biologically accurate description is thermally dimorphic fungi, organisms that exist as environmental molds and convert to invasive yeast or yeastlike forms at body temperature. For histoplasmosis, rigid geographic thinking is increasingly unhelpful. Modern epidemiologic studies using large health care data sets demonstrate that clinically recognized disease extends well beyond the classic Ohio and Mississippi River Valley narrative.^1,2 These findings do not imply uniform risk across all regions but rather emphasize that clinicians should avoid excluding the diagnosis solely because a patient lives outside historically recognized endemic areas. Genomic studies further suggest that what has historically been referred to as Histoplasma capsulatum represents a complex of phylogenetically distinct species (H. capsulatum sensu stricto, H. mississippiense, H. ohiense, H. suramericanum, and African clades), reflecting considerable evolutionary diversity within the organism.3 Most exposures to Histoplasma spp are believed to result in asymptomatic or self-limited infection.^4,5 Consequently, clinically recognized histoplasmosis represents only a small fraction of total infections. The clinical importance of histoplasmosis lies less in its overall incidence than in its capacity to cause severe disease in susceptible hosts and in the frequency with which diagnosis is delayed. Diagnostic delays are well documented. In a multicenter cohort study of confirmed histoplasmosis cases, the median time from symptom onset to diagnosis was 23 days.⁶

During this interval, patients often had multiple health care encounters and frequently received empiric antibacterial therapy before fungal infections were considered. Diagnostic delays may also lead to repeated imaging studies, invasive diagnostic procedures, and additional health care utilization before the correct diagnosis is established. Delayed recognition can also prolong unnecessary antibacterial exposure, increase hospital admissions, and contribute to additional diagnostic testing before fungal infections are ultimately identified. One setting in which this diagnostic gap becomes particularly visible is communityacquired pneumonia (CAP). Because infection begins with inhalation of environmental microconidia, pulmonary disease often represents the initial clinical manifestation. Yet fungal pathogens are rarely incorporated into routine CAP diagnostic algorithms. In a recent analysis of 573,994 adults with unspecified CAP, only 25,822 patients (5%) underwent testing for histoplasmosis, blastomycosis, or coccidioidomycosis.⁷ Testing occurred a median of 8 days after the index encounter and after a median of 3 health care visits, suggesting that clinicians typically considered fungal infection only after more common bacterial etiologies had been pursued. Nearly one-third of patients in the broader CAP cohort received antibiotics from more than one antimicrobial class, reflecting persistent symptoms, treatment failure, or diagnostic uncertainty. Additional analyses of this cohort also demonstrated substantial health care utilization, including repeated outpatient visits and emergency department encounters, before fungal testing was ultimately performed.

Among patients who were tested, approximately 3% received a diagnosis code for a thermally dimorphic mycosis. Because testing was performed in less than 5% of patients, these data cannot determine the true incidence of fungal CAP but highlight the potential magnitude of underrecognition. Interestingly, dimorphic fungal infections were approximately twice as frequent as legionellosis, an infection routinely included in CAP diagnostic algorithms.8 In contrast, testing for fungal pathogens was performed in less than 1 in 20 patients. This discrepancy suggests that fungal pathogens may contribute meaningfully to pulmonary syndromes yet remain underrepresented in routine diagnostic evaluations. Although pulmonary infection is the most common clinical manifestation, the most severe consequences of delayed diagnosis occur in disseminated histoplasmosis.

Disseminated infection occurs primarily in immunocompromised hosts and remains associated with substantial morbidity and mortality. Contemporary cohorts report mortality rates of approximately 10% to 15% in disseminated histoplasmosis cases, despite modern antifungal therapy, whereas death from localized pulmonary disease is uncommon.⁹ The burden of disseminated histoplasmosis is particularly striking among individuals with advanced HIV infection. Outside the US, histoplasmosis represents one of the most important opportunistic infections in patients with advanced HIV. Epidemiologic modeling studies estimate that more than 100,000 cases of HIV-associated histoplasmosis occur annually in Latin America, leading to approximately 30,000 to 50,000 deaths each year.¹⁰ In several regions, histoplasmosis may rival or exceed tuberculosis as a cause of death among patients with advanced HIV infection.¹¹ Diagnostic delay contributes substantially to these outcomes. In many parts of Latin America and other resource-limited settings, diagnosis still depends largely on fungal culture, which can require 2 to 3 weeks for growth and identification.^12,13 In contrast, antigen detection assays widely used in resource-rich settings can establish diagnosis within days. Limited access to rapid diagnostics and antifungal therapy, particularly liposomal amphotericin B, contributes to higher mortality in these settings, where outcomes may be worse than those observed in the US.^12-14 These disparities underscore the importance of improving access to rapid diagnostics and effective antifungal therapy in regions with the highest disease burden. At the same time, the population at risk for severe histoplasmosis continues to expand. Recent analyses estimate that 6.6% of US adults, more than 20 million individuals, are immunocompromised, including patients with malignancy, transplant recipients, individuals receiving corticosteroids, and increasing numbers treated with biologic or targeted immunomodulatory therapies.¹⁵ Risk varies across these groups, but the overall trend is unmistakable: The pool of patients susceptible to severe histoplasmosis is growing. Histoplasmosis following solid organ transplantation is well described, and severe disease has increasingly been reported among patients receiving tumor necrosis factor inhibitors and other biologic therapies.^4,5 As the use of immunomodulatory therapies continues to expand across multiple medical specialties, clinicians outside traditional transplant and HIV care settings are increasingly likely to encounter severe histoplasmosis. Diagnostic advances have improved the recognition of infection. Histoplasma antigen detection remains one of the most valuable tools for diagnosing disseminated disease. In disseminated histoplasmosis, particularly among patients with advanced HIV infection, urine antigen sensitivity exceeds 90% in many series.¹⁶ Test performance, however, is strongly syndrome dependent; sensitivity is substantially lower in localized pulmonary disease. Combining antigen detection with antibody testing can improve overall diagnostic sensitivity, particularly in pulmonary histoplasmosis.¹⁷ Molecular diagnostics may further improve detection in resource-rich settings. Polymerase chain reaction assays detecting Histoplasma DNA in blood or respiratory specimens have demonstrated sensitivities of roughly 70% to 90% in selected studies, although assays remain heterogeneous and are not yet standardized across laboratories.¹⁶ Meanwhile, lateral flow antigen assays may offer a practical path forward in resource-limited settings by enabling rapid, point-of-care detection.¹⁸ Early studies evaluating these assays suggest they may substantially shorten time to diagnosis in patients with disseminated disease.

Treatment strategies are also evolving. Current guidance recommends induction therapy with liposomal amphotericin B followed by prolonged itraconazole consolidation.¹⁹ A recent randomized trial evaluated a simplified regimen consisting of a single 10-mg/kg dose of liposomal amphotericin B compared with the conventional 3-mg/ kg daily regimen for 14 days in patients with HIV-associated disseminated histoplasmosis.²⁰ Clinical response rates were similar between groups. Simplified regimens such as this may improve access to lifesaving therapy in regions where prolonged intravenous antifungal treatment is difficult to deliver and where health systems face significant resource constraints.

Taken together, these observations support a clear conclusion: Histoplasmosis is broadly distributed, systematically underrecognized, and capable of causing severe disease in the hosts least able to tolerate diagnostic delay. It contributes to common clinical syndromes such as CAP, represents a major cause of death in advanced HIV infection globally, and may become increasingly important as the population of immunocompromised patients continues to expand. In that sense, histoplasmosis behaves less like a rare diagnostic zebra and more like a hard working donkey: common, persistent, and frequently overlooked.

References

1.Mazi PB, Sahrmann JM, Olsen MA, et al. The geographic distribution of dimorphic mycoses in the United States for the modern era. Clin Infect Dis. 2023;76(7):1295-1301. doi:10.1093/cid/ciac882

2.Bahr NC, Antinori S, Wheat LJ, Sarosi GA. Histoplasmosis infections worldwide: thinking outside of the Ohio River Valley. Curr Trop Med Rep. 2015;2(2):70-80. doi:10.1007/s40475-015-0044-0

3.Sepúlveda VE, Rader JA, Li J, Goldman WE, Matute DR. Phenotypic characterization of cryptic species in the fungal pathogen Histoplasma. mSphere. 2024;9(6):e0000924. doi:10.1128/msphere.00009-24

4.Wheat LJ, Azar MM, Bahr NC, Spec A, Relich RF, Hage C. Histoplasmosis. Infect Dis Clin North Am. 2016;30(1):207-227. doi:10.1016/j.idc.2015.10.009

5.Hage CA, Azar MM, Bahr N, Loyd J, Wheat LJ. Histoplasmosis: up-to-date evidence-based approach to diagnosis and management. Semin Respir Crit Care Med. 2015;36(5):729-745. doi:10.1055/s-0035-1562899

6.Benedict K, McCracken S, Signs K, et al. Enhanced surveillance for histoplasmosis-9 states, 2018-2019. Open Forum Infect Dis. 2020;7(9):ofaa343. doi:10.1093/ofid/ofaa343

7.Benedict K, Thompson GRIII, Ampel NM, Smith DJ, Toda M, Hennessee I. Blastomycosis, histoplasmosis, and coccidioidomycosis in outpatient community-acquired pneumonia. JAMA Netw Open. 2026;9(1):e2553965. doi:10.1001/jamanetworkopen.2025.53965

8.Smith DJ, Free RJ, Thompson GR III, et al; Endemic Mycoses Diagnostic Algorithm Subject Matter Expert Group. Clinical testing guidance for coccidioidomycosis, histoplasmosis, and blastomycosis in patients with community-acquired pneumonia for primary and urgent care providers. Clin Infect Dis. 2024;78(6):1559-1563. doi:10.1093/cid/ciad619

9.Dalton LM, Kauffman CA, Miceli MH. Characteristics and outcomes of hospitalized patients with histoplasmosis: comparison of immunocompromised and non-immunocompromised adult patients. J Fungi (Basel). 2025;11(9):671. doi:10.3390/jof11090671

10.Adenis AA, Valdes A, Cropet C, et al. Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: a modelling study. Lancet Infect Dis. 2018;18(10):1150-1159. doi:10.1016/S1473-3099(18)30354-2

11.Pasqualotto AC, Quieroz-Telles F. Histoplasmosis dethrones tuberculosis in Latin America. Lancet Infect Dis. 2018;18(10):1058-1060. doi:10.1016/S1473-3099(18)30373-6

12.Theel ES, Kus JV, Grys TE, Ampel NM, Schwartz IS, Zhang SX. Practical guidance for clinical microbiology laboratories: antibody and antigen detection methods for dimorphic fungal infections. Clin Microbiol Rev. 2025;38(2):e0000520. doi:10.1128/cmr.00005-20

13.Bongomin F, Kwizera R, Denning DW. Getting histoplasmosis on the map of international recommendations for patients with advanced HIV disease. J Fungi (Basel). 2019;5(3):80. doi:10.3390/jof5030080

14.Rodrigues ML, Nosanchuk JD. Fungal diseases as neglected pathogens: a wake-up call to public health officials. PLoS Negl Trop Dis. 2020;14(2):e0007964. doi:10.1371/journal.pntd.0007964

15.Martinson ML, Lapham J. Prevalence of immunosuppression among US adults. JAMA. 2024;331(10):880-882. doi:10.1001/jama.2023.28019

16.Caceres DH, Knuth M, Derado G, Lindsley MD. Diagnosis of progressive disseminated histoplasmosis in advanced HIV: a meta-analysis of assay analytical performance. J Fungi (Basel). 2019;5(3):76. doi:10.3390/jof5030076

17.Richer SM, Smedema ML, Durkin MM, et al. Improved diagnosis of acute pulmonary histoplasmosis by combining antigen and antibody detection. Clin Infect Dis. 2016;62(7):896-902. doi:10.1093/cid/ciw007

18.Matsuo T, Wurster S, Hoenigl M, Kontoyiannis DP. Current and emerging technologies to develop Point-of-Care Diagnostics in medical mycology. Expert Rev Mol Diagn. 2024;24(9):841-858. doi:10.1080/14737159.2024.2397515

19.Wheat LJ, Freifeld AG, Kleiman MB, et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7):807-825. doi:10.1086/521259

20.Pasqualotto AC, Lana DD, Godoy CSM, et al. Single high dose of liposomal amphotericin b in human immunodeficiency virus/AIDS-related disseminated histoplasmosis: a randomized trial. Clin Infect Dis. 2023;77(8):1126-1132. doi:10.1093/cid/ciad313